Recent news and events

See what we have been up to

Jun 05, 2023
CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics
May 15, 2023
Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-associated antigen for T cell cross presentation
May 02, 2022
CERo Therapeutics’ Multifunctional CER T Cells Synergize with Standard of Care Small Molecule Anti-Tumor Inhibitors Across Hematologic and Solid Tumor Models
Nov 12, 2021
CERo Therapeutics’ Novel Chimeric Engulfment Receptor T Cells Exhibit Multifunctional Properties and Enhanced Tumor Killing
Oct 25, 2021
CERo to Present at the Society of Immunotherapy for Cancer (SITC)
Mar 18, 2020
CERo Therapeutics Announces Research Collaboration with Lyell Immunopharma and Completion of Series A Financing